Portuguese Observational Re-Treatment Study of MabThera (PORTSMAB) - A Two-centre Observational Study in Sero-positive Rheumatoid Arthritis (RA) Patients Who Are Non-responders or Intolerant to a Single Tumor Necrosis Factor (TNF) Inhibitor.

Trial Profile

Portuguese Observational Re-Treatment Study of MabThera (PORTSMAB) - A Two-centre Observational Study in Sero-positive Rheumatoid Arthritis (RA) Patients Who Are Non-responders or Intolerant to a Single Tumor Necrosis Factor (TNF) Inhibitor.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2016

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms PORTSMAB
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 May 2013 Planned End Date changed from 1 Dec 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top